// App-Quantinova.ai

436 : INTENSIVE DOSE OF ROSUVASTATIN (40 MG/DAY), INITIATED EARLY AND CONTINUED FOR 12 WEEKS, IN VERY HIGH-RISK OR HIGH-RISK INDIAN PATIENTS

Researchers

Presenter

  • C. Shah

Principal Investigators

  • N/A

Medical Centers

  • Cardiology, Yashwantilika Hospital, Mumbai, India

Locations

  • India

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • High sensitivity C-reactive protein

Drug/Treatment

  • Rosuvastatin

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved